Silence Therapeutics Files 6-K, Incorporates Exhibits
Ticker: SLNCF · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-action, registration-statement
TL;DR
Silence Therapeutics filed a 6-K on 6/24, incorporating exhibits into existing S-8 filings. Nothing major, but check the exhibits.
AI Summary
Silence Therapeutics plc filed a Form 6-K on June 24, 2024, to report information for the month of June 2024. This filing includes Exhibit 99.1, which is incorporated by reference into their existing Form S-8 registration statements (File Nos. 333-248682 and 333-273576). The company is based in London, United Kingdom.
Why It Matters
This filing indicates ongoing regulatory and corporate actions for Silence Therapeutics, potentially affecting its stock and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine report and does not appear to contain significant new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- June 24, 2024 (date) — Filing Date
- 333-248682 (other) — Form S-8 File Number
- 333-273576 (other) — Form S-8 File Number
- London (location) — Company Headquarters
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed for the month of June 2024, and it incorporates Exhibit 99.1 by reference into existing registration statements.
Which registration statements are being updated by this filing?
Exhibit 99.1 is incorporated by reference into the registration statements on Form S-8, specifically File Nos. 333-248682 and 333-273576.
What is the filing date of this Form 6-K?
The Form 6-K was filed on June 24, 2024.
Where is Silence Therapeutics plc headquartered?
Silence Therapeutics plc is headquartered at 72 Hammersmith Road, London W14 8TH, United Kingdom.
Does Silence Therapeutics file annual reports under Form 20-F or 40-F?
Silence Therapeutics indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 303 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-06-24 08:38:26
Filing Documents
- d860461d6k.htm (6-K) — 10KB
- d860461dex991.htm (EX-99.1) — 10KB
- g860461g0622081902919.jpg (GRAPHIC) — 3KB
- 0001193125-24-166362.txt ( ) — 25KB
From the Filing
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INCORPORATION BY REFERENCE Exhibit 99.1 to this Report on Form 6-K (the Report) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Nos. 333-248682 and 333-273576) and the registration Silence Therapeutics plc (the Company) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated June 24, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated June 24, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SILENCE THERAPEUTICS PLC Date: June 24, 2024 By: /s/ Craig Tooman Craig Tooman President and Chief Executive Officer